SC0191
Phase 2Small molecule
SC0191 is one of 66 small molecule programs targeting Metastatic Colorectal Cancer. It is currently in Phase 2.
2
Indications
2
Total Trials
1
Active Trials
65
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
836 competitors in Ovarian Cancer
#DrugCompanyPhaseTrials
1Gemzar
Johnson & JohnsonPhase 3
Avastin
BBio-Thera Solutions
Phase 3
Imfinzi
AstraZenecaPhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Jemperli
GGlaxo Dba Glaxosmithkline
Phase 3
Arimidex
IIstituto Clinico Humanitas
Phase 3
H2 Receptor Antagonist
Merck & Co.Phase 3
Rina-S
GenmabPhase 3
Apatinib Mesylate
BBukwang Pharmaceutical
Phase 3
Salvage Chemotherapy
Daiichi SankyoPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SC0191. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details